Drugs / α-lactalbumin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04674306 | Oct 2021 → Dec 2025 | triple-negative breast carcinoma | George T. Budd | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2026-06-11 | Anixa Biosciences, Inc. | Results Anixa Biosciences Announces Presentations of Two Clinical-Stage Immunotherapy Programs at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium anixa.com ↗
The presentation will report final Phase 1 findings for the investigational vaccine, including that all major primary endpoints were met, the vaccine was safe and well tolerated at the maximum tolerated dose based on safety and tolerability, and protocol-defined immune responses were elicited in 74% of trial participants. |
| 2026-04-01 | Anixa Biosciences, Inc. | Results Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing anixa.com ↗
The agreement follows positive final Phase 1 results in which the investigational vaccine met all primary endpoints, was safe and well tolerated at the maximum tolerated dose, and generated protocol-defined immune responses in 74% of participants. |
| 2025-12-11 | Anixa Biosciences, Inc. | Results Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants anixa.com ↗
Final Phase 1 findings showed the investigational vaccine met all major primary endpoints, was safe and well tolerated at the maximum tolerated dose (MTD), and elicited protocol-defined immune responses in 74% of participants. |
| 2025-11-12 | Anixa Biosciences, Inc. | Regulatory Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s anixa.com ↗ |
| 2024-11-08 | Anixa Biosciences, Inc. | Results Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting anixa.com ↗
Protocol defined immune responses were exhibited in over 70% of patients |
| 2023-12-06 | Anixa Biosciences, Inc. | Results Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine anixa.com ↗
Among the doses studied, Dose Level 1 (10 mcg α-lactalbumin/10 mcg zymosan) was determined to be a usable immunologic dose as well as the maximum tolerated dose (MTD). |
| 2023-04-17 | Anixa Biosciences, Inc. | Results Anixa Biosciences and Cleveland Clinic Present Positive Data for Phase 1 Study of Breast Cancer Vaccine anixa.com ↗
The data presented showed that in the vaccinated women who have been tested to date, various levels of antigen-specific T cell responses were observed at all dose levels. |
| 2020-11-23 | Anixa Biosciences, Inc. | Regulatory Anixa Biosciences and Cleveland Clinic File IND Application for Breast Cancer Vaccine anixa.com ↗ |
All press releases naming this drug 8 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | α-lactalbumin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04674306 ↗ |
| Known as | α-lactalbumin vaccine | “α-lactalbumin vaccine will be administered subcutaneously in rotating sites” NCT04674306 ↗ |
| Modality | Vaccine | “This aLA breast cancer vaccine is an investigational (experimental) drug” NCT04674306 ↗ |
| Route | Subcutaneous | “α-lactalbumin vaccine will be administered subcutaneously in rotating sites” NCT04674306 ↗ |